REFERENCES
1. Picci P, Manfrini M, Donati DM, et al. Diagnosis of musculoskeletal tumors and tumor-like conditions 2nd edition. Switzerland: Springer Nature; 2020.
2. Bovée JVMG, Bloem JL, Flanagan AM, et al. WHO Classification of Tumours of Soft Tissue and Bone. 5th edition. Lyon: International Agency for research on cancer; 2020.
3. Unni KK, Inwards CY, Bridge JA, Kindblom LG, Wold LE. AFIP atlas of tumor pathology. Tumors of the bones and joints. 4th series. Washington, DC: The American Registry of Pathology; 2005.
4. Ahmed AR, Tan TS, Unni KK, Collins MS, Wenger DE, Sim FH. Secondary chondrosarcoma in osteochondroma: report of 107 patients. Clin Orthop Relat Res 2003:193-206.
5. Jones KB, Piombo V, Searby C, et al. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci U S A 2010;107:2054-9.
6. de Andrea CE, Wiweger M, Prins F, Bovée JV, Romeo S, Hogendoorn PC. Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma. Lab Invest 2010;90:1091-101.
7. Matsumoto K, Irie F, Mackem S, Yamaguchi Y. A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses. Proc Natl Acad Sci U S A 2010;107:10932-7.
8. Jennes I, Pedrini E, Zuntini M, et al. Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat 2009;30:1620-7.
9. de Andrea CE, Reijnders CM, Kroon HM, et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene 2012;31:1095-104.
10. Häcker U, Nybakken K, Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 2005;6:530-41.
11. Pacifici M. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses. Matrix Biol 2018;71-72:28-39.
12. Hallor KH, Staaf J, Bovée JV, et al. Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res 2009;15:2685-94.
13. de Andrea CE, Hogendoorn PC. Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. J Pathol 2012;226:219-28.
14. de Andrea CE, Zhu JF, Jin H, Bovée JV, Jones KB. Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency. J Pathol 2015;236:210-8.
15. Nielsen GP, Rosenberg AE, Deshpande V, Hornicek FJ, Kattapuram SV, Rosenthal DI. Diagnostic Pathology: Bone. 2nd ed. Philadelphia, PA: Elsevier; 2017.
16. Vanel D, De Paolis M, Monti C, Mercuri M, Picci P. Radiological features of 24 periosteal chondrosarcomas. Skeletal Radiol 2001;30:208-12.
17. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011;224:334-43.
18. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008;13:320-29.
19. van Maldegem AM, Gelderblom H, Palmerini E, et al. Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer 2014;120:3159-64.
20. Papagelopoulos PJ, Galanis EC, Mavrogenis AF, et al. Survivorship analysis in patients with periosteal chondrosarcoma. Clin OrthopRelat Res 2006;448:199-207.
21. Bertoni F, Boriani S, Laus M, Campanacci M. Periosteal chondrosarcoma and periosteal osteosarcoma. Two distinct entities. J Bone Joint Surg Br 1982;64:370-6.
22. Cleven AH, Zwartkruis E, Hogendoorn PC, et al. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype. Histopathology 2015;67:483-90.
23. Pansuriya TC, van Eijk R, d’Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011;43:1256-61.
24. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
25. Suijker J, Baelde HJ, Roelofs H, Cleton-Jansen AM, Bovée JV. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. Oncotarget 2015;6:14832-42.
26. Jin Y, Elalaf H, Watanabe M, et al. Mutant IDH1 dysregulates the differentiation of mesenchymal stem cells in association with gene-specific histone modifications to cartilage- and bone-related genes. PLoS One 2015;10:e0131998.
27. Czerniak B. Dorfman and Czerniak’s Bone Tumors. 2nd edition. Philadelphia: Saunders; 2016.
28. Goedhart LM, Ploegmakers JJ, Kroon HM, Zwartkruis EC, Jutte PC. The presentation, treatment and outcome of periosteal chondrosarcoma in the Netherlands. Bone Joint J 2014;96:823-8.
29. Ruengwanichayakun P, Gambarotti M, Frisoni T, et al. Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients. Hum Pathol 2019;91:11-8.
30. Bertoni F, Bacchini P, Staals EL, Davidovitz P. Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer 2005;10:2373-82.
31. Aparisi Gómez MP, Righi A, Errani C, et al. Inflammation and infiltration: can the radiologist draw a line? MRI versus CT to accurately assess medullary involvement in parosteal osteosarcoma. Int J Biol Markers 2020;35:31-6.
32. Reith JD, Donahue FI, Hornicek FJ. Dedifferentiated parosteal osteosarcoma with rhabdomyosarcomatous differentiation. Skeletal Radiol 1999;28:527-31.
33. Szymanska J, Mandahl N, Mertens F, et al. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: a combined cytogenetic and comparative genomic hybridization study. Genes Chromosomes Cancer 1996;16:31-4.
34. Dujardin F, Binh MB, Bouvier C, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol 2011;24:624-37.
35. Duhamel LA, Ye H, Halai D, et al. Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. Histopathology 2012;60:357-9.
36. Baumhoer D, Amary F, Flanagan AM. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes Cancer 2019;58:88-99.
37. Bekers EM, Eijkelenboom A, Grünberg K, et al. Myositis ossificans - another condition with USP6 rearrangement, providing evidence of a relationship with nodular fasciitis and aneurysmal bone cyst. Ann Diagn Pathol 2018;34:56-9.
38. Meneses MF, Unni KK, Swee RG. Bizarre parostealosteochondromatous proliferation of bone (Nora’s lesion). Am J Surg Pathol 1993;17:691-7.
39. Berber O, Dawson-Bowling S, Jalgaonkar A, et al. Bizarre parostealosteochondromatous proliferation of bone: clinical management of a series of 22 cases. J Bone Joint Surg Br 2011;93:1118-21.
40. Abramovici L, Steiner GC. Bizarre parostealosteochondromatous proliferation (Nora’s lesion): a retrospective study of 12 cases, 2 arising in long bones. Hum Pathol 2002;3:1205-10.
41. Lewis VO, Gebhardt MC, Springfield DS. Parosteal osteosarcoma of the posterior aspect of the distal part of the femur. Oncological and functional results following a new resection technique. J Bone Joint Surg Am 2000;82:1083-8.
42. Han I, Oh JH, Na YG, Moon KC, Kim HS. Clinical outcome of parosteal osteosarcoma. J Surg Oncol 2008;97:146-9.
43. Laitinen M, Parry M, Albergo JI, et al. The prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma. Bone Joint J 2015;97:1698-703.
44. Cesari M, Alberghini M, Vanel D, et al. Periosteal osteosarcoma: a single-institution experience. Cancer 2011;117:1731-5.
45. Chan CM, Lindsay AD, Spiguel ARV, Gibbs CP Jr, Scarborough MT. Periosteal Osteosarcoma: a single-institutional study of factors related to oncologic outcomes. Sarcoma 2018;2018:8631237.
46. Grimer RJ, Bielack S, Flege S, et al. Periosteal osteosarcoma:a European review of outcome. Eur J Cancer 2005;41:2806-11.
47. Righi A, Gambarotti M, Benini S, et al. MDM2 and CDK4 expression in periosteal osteosarcoma. Hum Pathol 2015;46:549-53.
48. Ritts GD, Pritchard DJ, Unni KK, Beabout JW, Eckardt JJ. Periosteal osteosarcoma. Clin Orthop Relat Res 1987;219:299-307.
49. Okada K, Unni KK, Swee RG, Sim FH. High grade surface osteosarcoma: a clinicopathologic study of 46 cases. Cancer 1999;85:1044-54.
